Phase 2 study of mapatumumab for the treatment of advanced multiple myeloma

Human Genome Sciences announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with Velcade (bortezomib) in patients with advanced multiple myeloma. The results showed no difference in disease response or progression-free survival for the combination that included mapatumumab vs. the control group receiving bortezomib alone, and showed that mapatumumab was well tolerated in this study.

Mapatumumab is an agonistic human monoclonal antibody that directly induces cancer cell death by specifically binding to and activating the protein known as TRAIL receptor 1.

For more information call (877) 822-8472 or visit www.hgsi.com.